{
    "medicine_id": "3d2c595c4297177d3b22d5835e74d9d31f588ad2",
    "platform_id": "4992",
    "metadata": {
        "name": "PREZISTA 150 mg film coated tablets",
        "composition": "PREZISTA 150 mg film coated tablets Each film coated tablet contains 150 mg of darunavir as ethanolate For the full list of",
        "clinical_particulars": {
            "therapeutic_indications": "PREZISTA co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus HIV 1 infection see section 4 2 PREZISTA 75 mg 150 mg and 600 mg tablets may be used to provide suitable dose regimens see section 4 2 In deciding to initiate treatment with PREZISTA co administered with low dose ritonavir careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents Genotypic or phenotypic testing when available and treatment history should guide the use of PREZISTA see sections 4 2 4 4 and 5 1",
            "contraindications": {
                "disease": "Hypersensitivity to the active substance or to any of the excipients listed in section 6 1 Patients with severe Child Pugh Class C hepatic impairment Combination of strong CYP3A inducers such as rifampicin with PREZISTA with concomitant low dose ritonavir see section 4 5 Co administration with the combination product lopinavir ritonavir see section 4 5 Co administration with herbal preparations containing St John s Wort Hypericum perforatum see section 4 5 Co administration of PREZISTA with low dose ritonavir with active substances that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and or life threatening events These active substances include e g alfuzosin amiodarone bepridil dronedarone ivabradine quinidine ranolazine astemizole terfenadine colchicine when used in patients with renal and or hepatic impairment see section 4 5 ergot derivatives e g dihydroergotamine ergometrine ergotamine methylergonovine elbasvir grazoprevir cisapride dapoxetine domperidone naloxegol lurasidone pimozide quetiapine sertindole see section 4 5 triazolam midazolam administered orally for caution on parenterally administered midazolam see section 4 5 sildenafil when used for the treatment of pulmonary arterial hypertension avanafil simvastatin lovastatin and lomitapide see section 4 5 dabigatran ticagrelor see section 4 5",
                "pregnancy": "Applicable",
                "machine_ops": "Applicable",
                "excipients": "Microcrystalline cellulose;Colloidal anhydrous silica;Crospovidone;Magnesium stearate;Poly(vinyl alcohol) \u2013 partially hydrolysed;Macrogol 3350;Titanium dioxide (E171);Talc",
                "incompatibilities": "Not applicable."
            }
        },
        "revision_date": "2022-09-30"
    }
}